• Guido Iaccarino, Claudio Borghi, Cicero Arrigo F G AFG http://orcid.org/0000-0002-4367-3884 Department of Medicine and Surgery Sciences, Alma Mater Studiorum University of Bologna, Bo, Claudio Ferri, Pietro Minuz, Maria Lorenza Muiesan, Paolo Mulatero, Giuseppe Mulè, Giacomo Pucci, Massimo Salvetti, Carmine Savoia, Leonardo Alberto Sechi, Massimo Volpe, and Guido Grassi.
• Department of Advanced Biomedical Sciences, Federico II University, Naples, Italy.
• High Blood Press Cardiovasc Prev. 2020 Apr 1; 27 (2): 105-108.

AbstractCardiovascular diseases, in particular hypertension, as well as the cardiovascular treatment with Renin-Angiotensin System inhibitors such as Angiotensin Converting Enzyme (ACE) inhibitors and Angiotensin Receptor Blockers (ARBs), are claimed once again as mechanisms of Severe Acute Respiratory Syndrome (SARS) during the COVID-19 outbreak due to Cov-2 epidemics. In vitro studies are available to support the eventual role of ACE inhibitors and ARBs in both the promotion and antagonism of the disease. The available literature, indeed, presents contrasting results, all concentrated in experimental models. Evidence in humans is lacking that those mechanisms are actually occurring in the present COVID-19 outbreak. Here we present the reasoned statement of the Italian Society of Hypertension to maintain ongoing antihypertensive treatments. Furthermore, the Italian Society of Hypertension presents its own initiative to investigate the issue using an online questionnaire to collect relevant data in human disease.

27 keywords...

hide…